EPITHELIOID HEMANGIOENDOTHELIOMA
Clinical trials for EPITHELIOID HEMANGIOENDOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new EPITHELIOID HEMANGIOENDOTHELIOMA trials appear
Sign up with your email to follow new studies for EPITHELIOID HEMANGIOENDOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets rare, aggressive cancer
Disease control Recruiting nowThis phase 2 trial is testing whether combining two chemotherapy drugs—Abraxane and liposomal doxorubicin—can shrink tumors in people with advanced or unresectable angiosarcoma, a rare and aggressive cancer of blood vessels. The study will enroll 69 patients who have already trie…
Matched conditions: EPITHELIOID HEMANGIOENDOTHELIOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill could help immune system fight rare sarcomas
Disease control Recruiting nowThis phase 2 trial tests an experimental oral drug called ABSK043 in about 20 people with rare sarcomas (intimal sarcoma, head/neck angiosarcoma, or EHE). The drug blocks PD-L1, which may help the immune system recognize and kill cancer cells. The main goal is to see if tumors sh…
Matched conditions: EPITHELIOID HEMANGIOENDOTHELIOMA
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for advanced cancers: first human trial of ODM-212 begins
Disease control Recruiting nowThis study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…
Matched conditions: EPITHELIOID HEMANGIOENDOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Scientists launch international registry to crack the code of ultra-rare cancer EHE
Knowledge-focused Recruiting nowThis study creates a registry to collect information from 100 adults newly diagnosed with epithelioid hemangioendothelioma (EHE), an ultra-rare sarcoma. Researchers will track patients over time to understand how the disease progresses, what factors affect outcomes, and which tre…
Matched conditions: EPITHELIOID HEMANGIOENDOTHELIOMA
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Scientists launch deep dive into rare sarcomas to unlock immune secrets
Knowledge-focused Recruiting nowThis study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could le…
Matched conditions: EPITHELIOID HEMANGIOENDOTHELIOMA
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC